Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsIngo K. Mellinghoff, Paul S. Mischel, Maria Y. Wang et al.|New England Journal of Medicine|2005Cited by 1.4k
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to gliomaRameen Beroukhim, William R. Sellers, Gad Getz et al.|Proceedings of the National Academy of Sciences|2007Cited by 1.1k
High-throughput oncogene mutation profiling in human cancerRoman K. Thomas, Meenhard Herlyn, Alissa C. Baker et al.|Nature Genetics|2007Cited by 996
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 540
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in MedulloblastomaNataliya Zhukova, Rebecca M. Hill, Dominik Sturm et al.|Journal of Clinical Oncology|2013Cited by 488